Literature DB >> 19627296

Effusive constrictive pericarditis.

Rajeev Garg1, Avneet Singh, Anand Chockalingam.   

Abstract

Effusive constrictive pericarditis (ECP) is a relatively infrequent pericardial condition. The diagnosis is typically made when symptoms and right heart pressure elevation persist despite drainage of pericardial effusion. Visceral and parietal pericardial stripping is an extensive procedure with significant morbidity and mortality but is widely considered the only effective treatment. Recent studies suggest that up to 10% of constriction may be reversible, and a newer series has reported spontaneous complete resolution of symptoms in a subset of ECP patients. In this review, the authors describe 2 patients with ECP who were managed successfully with steroids and colchicine, respectively, thus obviating the need for surgery. The authors also review the current understanding of this reversible pericardial pathology and explore the possible role for colchicine in treating this condition.

Entities:  

Mesh:

Year:  2009        PMID: 19627296     DOI: 10.1111/j.1751-7133.2008.00032.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  4 in total

1.  Effusive-constrictive pericarditis in the absence of overt pericardial disease on multiple imaging modalities.

Authors:  Julia Dawn Jones; Reza Ashrafi; Steffan P McDougall; Aleem U Khand
Journal:  BMJ Case Rep       Date:  2011-12-01

Review 2.  Effusive-constrictive pericarditis.

Authors:  Faisal F Syed; Mpiko Ntsekhe; Bongani M Mayosi; Jae K Oh
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

3.  Effusive-Constrictive Pericarditis Secondary to Primary Pericardial Lymphoma: A Case Report.

Authors:  Mauricio Anaya-Cisneros; Matthew S Tong; Alejandro R Calvo
Journal:  World J Oncol       Date:  2012-04-23

4.  Surgical management of effusive constrictive pericarditis.

Authors:  Fuat Buyukbayrak; Eray Aksoy; Serpil Tas; Kaan Kirali
Journal:  Cardiovasc J Afr       Date:  2013-09-16       Impact factor: 1.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.